Literature DB >> 20587624

Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo.

Irma Kuipers1, Jiang Li, Inge Vreeswijk-Baudoin, Johan Koster, Pim van der Harst, Herman H W Silljé, Folkert Kuipers, Dirk J van Veldhuisen, Wiek H van Gilst, Rudolf A de Boer.   

Abstract

AIMS: Liver X receptor (LXR) is a nuclear receptor regulating cholesterol metabolism. Liver X receptor has also been shown to exert anti-proliferative and anti-inflammatory properties. In this study, we evaluated the effect of LXR activation on cardiac hypertrophy in vitro and in vivo. METHODS AND
RESULTS: Treatment with the synthetic LXR agonist T0901317 (T09) attenuated the hypertrophic response of cultured cardiomyocytes to endothelin-1 almost to control levels. siRNA interference showed that this effect was indeed LXR specific. To corroborate these findings in vivo, abdominal aortic constriction (AC) was used as a pressure overload model to induce cardiac hypertrophy in wild-type and LXR-α-deficient (LXR-α(-/-)) mice. In wild-type mice, T09 treatment resulted in a decrease of cardiac wall thickening 4 and 7 weeks after AC. Also, after 7 weeks of AC, mean arterial blood pressure and left ventricular weight/body weight (LVW/BW) ratios were decreased in T09 treated mice. These effects were not observed in LXR-α(-/-) mice, indicating that the beneficial effect of LXR activation on cardiac hypertrophy is attributable to the LXR-α isoform. T09 induced robust cardiac expression of metabolic genes which are downstream of LXR-α, such as SREBP-1c, ABCA1, and ABCG1.
CONCLUSION: Together these results indicate that LXR exerts salutary effects in cardiac hypertrophy, possibly via metabolic remodelling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20587624     DOI: 10.1093/eurjhf/hfq109

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  17 in total

1.  Increased mortality and aggravation of heart failure in liver X receptor-α knockout mice after myocardial infarction.

Authors:  Xiaoqiang Liu; Jianshu Gao; Qiang Xia; Tianfei Lu; Fang Wang
Journal:  Heart Vessels       Date:  2016-01-11       Impact factor: 2.037

2.  Activation of liver-X-receptor α but not liver-X-receptor β protects against myocardial ischemia/reperfusion injury.

Authors:  Qing He; Jun Pu; Ancai Yuan; Wayne Bond Lau; Erhe Gao; Walter J Koch; Xin-Liang Ma; Ben He
Journal:  Circ Heart Fail       Date:  2014-10-02       Impact factor: 8.790

3.  52 Genetic Loci Influencing Myocardial Mass.

Authors:  Pim van der Harst; Jessica van Setten; Niek Verweij; Georg Vogler; Lude Franke; Matthew T Maurano; Xinchen Wang; Irene Mateo Leach; Mark Eijgelsheim; Nona Sotoodehnia; Caroline Hayward; Rossella Sorice; Osorio Meirelles; Leo-Pekka Lyytikäinen; Ozren Polašek; Toshiko Tanaka; Dan E Arking; Sheila Ulivi; Stella Trompet; Martina Müller-Nurasyid; Albert V Smith; Marcus Dörr; Kathleen F Kerr; Jared W Magnani; Fabiola Del Greco M; Weihua Zhang; Ilja M Nolte; Claudia T Silva; Sandosh Padmanabhan; Vinicius Tragante; Tõnu Esko; Gonçalo R Abecasis; Michiel E Adriaens; Karl Andersen; Phil Barnett; Joshua C Bis; Rolf Bodmer; Brendan M Buckley; Harry Campbell; Megan V Cannon; Aravinda Chakravarti; Lin Y Chen; Alessandro Delitala; Richard B Devereux; Pieter A Doevendans; Anna F Dominiczak; Luigi Ferrucci; Ian Ford; Christian Gieger; Tamara B Harris; Eric Haugen; Matthias Heinig; Dena G Hernandez; Hans L Hillege; Joel N Hirschhorn; Albert Hofman; Norbert Hubner; Shih-Jen Hwang; Annamaria Iorio; Mika Kähönen; Manolis Kellis; Ivana Kolcic; Ishminder K Kooner; Jaspal S Kooner; Jan A Kors; Edward G Lakatta; Kasper Lage; Lenore J Launer; Daniel Levy; Alicia Lundby; Peter W Macfarlane; Dalit May; Thomas Meitinger; Andres Metspalu; Stefania Nappo; Silvia Naitza; Shane Neph; Alex S Nord; Teresa Nutile; Peter M Okin; Jesper V Olsen; Ben A Oostra; Josef M Penninger; Len A Pennacchio; Tune H Pers; Siegfried Perz; Annette Peters; Yigal M Pinto; Arne Pfeufer; Maria Grazia Pilia; Peter P Pramstaller; Bram P Prins; Olli T Raitakari; Soumya Raychaudhuri; Ken M Rice; Elizabeth J Rossin; Jerome I Rotter; Sebastian Schafer; David Schlessinger; Carsten O Schmidt; Jobanpreet Sehmi; Herman H W Silljé; Gianfranco Sinagra; Moritz F Sinner; Kamil Slowikowski; Elsayed Z Soliman; Timothy D Spector; Wilko Spiering; John A Stamatoyannopoulos; Ronald P Stolk; Konstantin Strauch; Sian-Tsung Tan; Kirill V Tarasov; Bosco Trinh; Andre G Uitterlinden; Malou van den Boogaard; Cornelia M van Duijn; Wiek H van Gilst; Jorma S Viikari; Peter M Visscher; Veronique Vitart; Uwe Völker; Melanie Waldenberger; Christian X Weichenberger; Harm-Jan Westra; Cisca Wijmenga; Bruce H Wolffenbuttel; Jian Yang; Connie R Bezzina; Patricia B Munroe; Harold Snieder; Alan F Wright; Igor Rudan; Laurie A Boyer; Folkert W Asselbergs; Dirk J van Veldhuisen; Bruno H Stricker; Bruce M Psaty; Marina Ciullo; Serena Sanna; Terho Lehtimäki; James F Wilson; Stefania Bandinelli; Alvaro Alonso; Paolo Gasparini; J Wouter Jukema; Stefan Kääb; Vilmundur Gudnason; Stephan B Felix; Susan R Heckbert; Rudolf A de Boer; Christopher Newton-Cheh; Andrew A Hicks; John C Chambers; Yalda Jamshidi; Axel Visel; Vincent M Christoffels; Aaron Isaacs; Nilesh J Samani; Paul I W de Bakker
Journal:  J Am Coll Cardiol       Date:  2016-09-27       Impact factor: 24.094

4.  Activation of liver X receptor inhibits OCT2-mediated organic cation transport in renal proximal tubular cells.

Authors:  Teerasak Wongwan; Suticha Kittayaruksakul; Nithi Asavapanumas; Varanuj Chatsudthipong; Sunhapas Soodvilai
Journal:  Pflugers Arch       Date:  2017-07-25       Impact factor: 3.657

5.  Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization.

Authors:  Megan V Cannon; Herman H W Silljé; Jürgen W A Sijbesma; Inge Vreeswijk-Baudoin; Jolita Ciapaite; Bart van der Sluis; Jan van Deursen; Gustavo J J Silva; Leon J de Windt; Jan-Åke Gustafsson; Pim van der Harst; Wiek H van Gilst; Rudolf A de Boer
Journal:  EMBO Mol Med       Date:  2015-09       Impact factor: 12.137

6.  Liver X receptor agonist treatment attenuates cardiac dysfunction in type 2 diabetic db/db mice.

Authors:  Qing He; Jun Pu; Ancai Yuan; Tianbao Yao; Xiaoying Ying; Yichao Zhao; Longwei Xu; Huan Tong; Ben He
Journal:  Cardiovasc Diabetol       Date:  2014-11-22       Impact factor: 9.951

7.  Celecoxib prevents pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress.

Authors:  Chi Zhang; Fan Wang; Yingxia Zhang; Yimin Kang; Haisheng Wang; Mingming Si; Liping Su; Xue Xin; Feng Xue; Fei Hao; Lechu Yu; Jinzhong Xu; Yanlong Liu; Mingming Xue
Journal:  J Cell Mol Med       Date:  2015-10-29       Impact factor: 5.310

8.  Neopterin negatively regulates expression of ABCA1 and ABCG1 by the LXRα signaling pathway in THP-1 macrophage-derived foam cells.

Authors:  Jin-quan Yan; Chun-zhi Tan; Jin-hua Wu; Dong-cui Zhang; Ji-ling Chen; Bin-yuan Zeng; Yu-ping Jiang; Jin Nie; Wei Liu; Qin Liu; Hao Dai
Journal:  Mol Cell Biochem       Date:  2013-04-07       Impact factor: 3.396

9.  Munc18c in adipose tissue is downregulated in obesity and is associated with insulin.

Authors:  Lourdes Garrido-Sanchez; Xavier Escote; Leticia Coin-Aragüez; Jose Carlos Fernandez-Garcia; Rajaa El Bekay; Joan Vendrell; Eduardo Garcia-Fuentes; Francisco J Tinahones
Journal:  PLoS One       Date:  2013-05-20       Impact factor: 3.240

10.  Cardiac function and architecture are maintained in a model of cardiorestricted overexpression of the prorenin-renin receptor.

Authors:  Hasan Mahmud; Wellington Mardoqueu Candido; Linda van Genne; Inge Vreeswijk-Baudoin; Hongjuan Yu; Bart van de Sluis; Jan van Deursen; Wiek H van Gilst; Herman H W Silljé; Rudolf A de Boer
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.